Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics' stock experienced a 7.41% price decrease on August 15, 2025, following a report by Scorpion Capital alleging Vykat XR was overpriced and potentially unsafe, with an additional 4.9% decline the next day. In the month leading up to October 21, 2025, the shares climbed nearly 20%, recovering some ground after a period of volatility. As of October 20, 2025, the share price was $65.45, marking a 21.77% increase from $53.75 on October 21, 2024. The company's market capitalization stood at $3.41 billion as of October 27, 2025, with the stock trading at $64.18 and having a price range between $42.54 and $88.49 over the past year. Soleno Therapeutics also reported a quarterly EPS of -$0.09, surpassing estimates, and revenue of $32.66 million, exceeding consensus expectations, prior to October 26, 2025.

No specific information regarding demand seasonality for Soleno Therapeutics, Inc.'s products or services was found in the provided search results. As a clinical-stage biotechnology company focused on rare diseases, traditional demand seasonality patterns observed in other industries may not directly apply.

Soleno Therapeutics, Inc. operates in the biotechnology sector, focusing on developing treatments for rare diseases. Their primary product, Diazoxide Choline Extended-Release tablets (Vykat XR), is in late-stage clinical trials for Prader-Willi Syndrome.

Soleno Therapeutics, Inc. is based in Redwood City, California. The search results do not explicitly detail its broader geographic market reach or operational footprint beyond its headquarters.

Soleno Therapeutics' brand reputation has faced mixed assessments and legal scrutiny in the past year. Weiss Ratings reaffirmed a "sell (D-)" rating, while other analysts issued "buy" ratings, resulting in an average "Moderate Buy" rating and a consensus target price of $115.92. A report by Scorpion Capital alleging Vykat XR was overpriced and potentially unsafe led to investigations by law firms into potential securities fraud. Despite these challenges, the company's media sentiment score is positive at 0.84.

Soleno Therapeutics' ownership is a mix of institutional, retail, and individual investors. Approximately 36.27% of the company's stock is owned by Institutional Investors, 10.06% by Insiders, and 53.66% by Public Companies and Individual Investors. Another source indicates that approximately 25.38% of the stock is held by Institutional Investors and 10.89% by Public Companies and Individual Investors. There are 510 institutional owners holding a total of 63,742,006 shares. Major institutional shareholders include Janus Henderson Group Plc, Vivo Capital, LLC, Adage Capital Partners Gp, L.l.c., Price T Rowe Associates Inc /md/, Fmr Llc, BlackRock, Inc., Vanguard Group Inc, Avoro Capital Advisors LLC, Citadel Advisors Llc, and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. Vivo Opportunity, LLC is noted as owning the most shares.